Estrella Immunopharma, Inc.
ESLA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001844417
No open-market purchases or sales by Estrella Immunopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $4.99M in total; no superinvestor holds it.
Other share classesESLAW
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Estrella Immunopharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Estrella Immunopharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Liu Cheng | CEO | 397,437 | Aug 26, 2026 | 1 |
| Xu Jiandong | Chief Financial Officer | 365,488 | Aug 25, 2026 | 2 |
| Altman Jeffrey A | 10% Owner | 0Indirect | Oct 5, 2023 | 0 |
| Owl Creek Asset Management, L.P. | 10% Owner | 0Indirect | Oct 5, 2023 | 0 |
| Yang Weiguang | Other: Former Co-CEO and Director | – | Oct 2, 2023 | 0 |
| TradeUP Acquisition Sponsor LLC | Other: Former 10% owner | – | Oct 2, 2023 | 0 |
| Jiang Tao | Other: Former Director | – | Oct 2, 2023 | 0 |
| Wen Luqi | Other: Former CFO | – | Oct 2, 2023 | 0 |
| Li Jianwei | Other: Former Co-CEO and Director | 1,253,730 | Oct 2, 2023 | 0 |
| Twigg Weston | Other: Former Director | – | Oct 2, 2023 | 0 |
| Long James | Other: Former Director | – | Oct 2, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 (view filing) | Sep 11-Oct 7, 2025 | 230 daysLate | Xu JiandongChief Financial Officer | PPurchaseCommon Stock, par value $0.0001 per share | +1.10K | $1.30 | +$1.43K | +0.4%265.5K after | 2 lots |
| Apr 29, 2026 (view filing) | Sep 22, 2025 | 219 daysLate | Xu JiandongChief Financial Officer | PPurchaseCommon Stock, par value $0.0001 per share | +1.00K | $1.16 | +$1.16K | +6.4%16.7K after | |
| Mar 17, 2022 (view filing) | Mar 4 | 13 daysLate | Li JianweiCo-Chief Executive Officer | PPurchase | +142.0K | $314,700.00 | +$44.7B | +12.8%1.25M after | Price outlier |